ABSTRACT
Granulomas are inflammatory tissue responses directed to a set of antigens. Trapped Schistosoma mansoni eggs promote productive granulomas in the tissues, and they are the main damage caused by schistosomiasis. Some S. mansoni antigenic proteins may have a direct involvement in the resolution of the granulomatous response. The ATP diphosphohydrolases isoforms of this parasite are immunogenic, expressed in all phases of the parasite life cycle and secreted by eggs and adult worms. Potato apyrase is a vegetable protein that cross-reactive with parasite ATP diphosphohydrolases isoforms. In this study, the vegetable protein was purified, before being inoculated in C57BL/6 mice that were later infected with cercariae. Sixty days after infection, adult worms were recovered, antibodies and cytokines were measured, and morphological granuloma alterations evaluated. Immunization of the animals induced significant levels of IgG and IgG1 antibodies and IFN-γ, IL-10 and IL-5 cytokines, but not IL-13, suggesting that potato apyrase is an immunoregulatory protein. Supporting this hypothesis, it was found that liver damage associated with schistosomiasis was mitigated, reducing the size of the areas affected by granuloma to 35% and increasing the presence of multinucleated giant cells in this environment. In conclusion, potato apyrase was found to be effective immunomodulatory antigen for murine schistosomiasis.
Subject(s)
Apyrase/chemistry , Giant Cells/drug effects , Rodent Diseases/parasitology , Schistosoma mansoni/physiology , Schistosomiasis mansoni/veterinary , Solanum tuberosum/chemistry , Animals , Female , Mice , Mice, Inbred C57BL , Schistosoma mansoni/drug effects , Schistosomiasis mansoni/parasitology , Solanum tuberosum/enzymologyABSTRACT
Schistosomiasis mansoni presents many clinical manifestations during migration of schistosomes in their hosts, including diarrhea, hepatomegaly, splenomegaly, liver abscesses, skinlesions, brain tumors and myeloradiculopathy. No lesions have been reported in skeletal striated muscles due to schistosomiasis mansoni in the literature. This short communication reports the histopathological findings on skeletal musculature in a murine model of neuroeschistosomiasis mansoni. Lesions were found in the tongue, masseter muscle, buccinator muscle, digastric muscle and temporalis muscle. Worm recovery was carried out to confirm the infection. We describe here, for the first time in the literature, injuries in the skeletal musculature due to Schistosoma mansoni nfection.
Subject(s)
Granuloma/pathology , Granuloma/parasitology , Muscle, Striated/pathology , Muscle, Striated/parasitology , Neuroschistosomiasis/pathology , Schistosomiasis mansoni/pathology , Animals , Disease Models, Animal , Male , MiceABSTRACT
The Global Burden of Disease Study 2010 listed schistosomiasis among the leading 100 causes of death in Brazil, responsible for 3.6% of the estimated total of deaths globally. Eye and adnexa are very rarely affected by schistosomiasis mansoni, with limited documentation of ocular pathology in this setting. This short communication reports ocular histolopathological findings in a murine model of neuroschistosomiasis mansoni. Lesions were found in the bulbar conjunctiva, lacrimal gland, choroid and corneoscleral limbus.
Subject(s)
Eye Infections, Parasitic/parasitology , Neuroschistosomiasis/parasitology , Schistosomiasis mansoni/parasitology , Animals , Brazil , Disease Models, Animal , Eye Infections, Parasitic/pathology , Eye Infections, Parasitic/physiopathology , Male , Mice , Neuroschistosomiasis/pathology , Neuroschistosomiasis/physiopathology , Schistosoma mansoni/isolation & purification , Schistosomiasis mansoni/pathology , Schistosomiasis mansoni/physiopathologyABSTRACT
Eukaryotic protein kinases (ePKs) are good medical targets for drug development in different biological systems. ePKs participate in many cellular processes, including the p38 MAPK regulation of homeostasis upon oxidative stress. We propose to assess the role of Smp38 MAPK signaling pathway in Schistosoma mansoni development and protection against oxidative stress, parasite survival, and also to elucidate which target genes have their expression regulated by Smp38 MAPK. After a significant reduction of up to 84% in the transcription level by Smp38 MAPK gene knockdown, no visible phenotypic changes were reported in schistosomula in culture. The development of adult worms was tested in vivo in mice infected with the Smp38 knocked-down schistosomula. It was observed that Smp38 MAPK has an essential role in the transformation and survival of the parasites as a low number of adult worms was recovered. Smp38 knockdown also resulted in decreased egg production, damaged adult worm tegument, and underdeveloped ovaries in females. Furthermore, only ~13% of the eggs produced developed into mature eggs. Our results suggest that inhibition of the Smp38 MAPK activity interfere in parasites protection against reactive oxygen species. Smp38 knockdown in adult worms resulted in 80% reduction in transcription levels on the 10th day, with consequent reduction of 94.4% in oviposition in vitro. In order to search for Smp38 MAPK pathway regulated genes, we used an RNASeq approach and identified 1,154 DEGs in Smp38 knockdown schistosomula. A substantial proportion of DEGs encode proteins with unknown function. The results indicate that Smp38 regulates essential signaling pathways for the establishment of parasite homeostasis, including genes related to antioxidant defense, structural composition of ribosomes, spliceosomes, cytoskeleton, as well as, purine and pyrimidine metabolism pathways. Our data show that the Smp38 MAPK signaling pathway is a critical route for parasite development and may present attractive therapeutic targets for the treatment and control of schistosomiasis.
Subject(s)
Schistosoma mansoni/physiology , Schistosomiasis mansoni/parasitology , p38 Mitogen-Activated Protein Kinases/metabolism , Animals , Computational Biology , Gene Expression , Gene Expression Profiling , Gene Knockdown Techniques , Life Cycle Stages , MAP Kinase Signaling System , Mice , Oviposition , Oxidative Stress , Protein Kinase Inhibitors/pharmacology , Schistosoma mansoni/anatomy & histology , Schistosoma mansoni/drug effects , Schistosomiasis mansoni/drug therapy , p38 Mitogen-Activated Protein Kinases/geneticsABSTRACT
The helminth Schistosoma mansoni is one of main causes of human schistosomiasis, a health and economic concern in some of the world's poorest countries. Current treatment regimens can lead to serious side effects and are not suitable for breastfeeding mothers. As such, efforts have been undertaken to develop a vaccine to prevent infection. Of these, Sm29 is a promising candidate that has been associated with resistance to infection/reinfection in humans and mice. Its ability to induce resistance to reinfection has also been recently demonstrated using a vaccine formulation containing Freund's adjuvant. However, Freund's adjuvant is unsuitable for use in human vaccines. We therefore evaluated the ability of Sm29 to induce protection against S. mansoni reinfection when formulated with either alum or MPLA as an adjuvant, both approved for human use. Our data demonstrate that, in contrast to Sm29 with MPLA, Sm29 with alum reduced parasite burden after reinfection compared to a control. We next investigated whether the immune response was involved in creating the differences between the protective (Sm29Alum) and non-protective (Sm29MPLA) vaccine formulations. We observed that both formulations induced a similar mixed-profile immune response, however, the Sm29 with alum formulation raised the levels of antibodies against Sm29. This suggests that there is an association between a reduction in worm burden and parasite-specific antibodies. In summary, our data show that Sm29 with an alum adjuvant can successfully protect against S. mansoni reinfection in mice, indicating a potentially effective vaccine formulation that could be applied in humans.
Subject(s)
Antigens, Helminth/immunology , Immunity, Humoral , Schistosoma mansoni/physiology , Schistosomiasis mansoni/immunology , Vaccines/immunology , Adjuvants, Immunologic/administration & dosage , Adjuvants, Immunologic/chemistry , Alum Compounds/administration & dosage , Alum Compounds/chemistry , Animals , Antibodies, Helminth/blood , Antigens, Helminth/chemistry , Disease Resistance , Female , Humans , Mice , Mice, Inbred BALB C , VaccinationABSTRACT
The impact of ivermectin on adult snails of the genus Biomphalaria (B. glabrata, B. tenagophila and B. straminea), B. glabrata infected with Schistosoma mansoni, snail egg-masses cercariae and miracidia, as well as on guppy fish (Poecilia reticulata) was examined and evaluated. Biomphalaria snails, egg-masses, parasite stages and guppies were all exposed to different concentrations of ivermectin for 24 h, followed by regular observations of mortality. The calculated lethal doses of ivermectin were around an LD50 of 0.03 µg ml-1, and an LD90 of 0.3 µg ml-1 for the three species of snails. Specimens of B. glabrata actually shedding parasite cercariae all died when exposed to ivermectin at a concentration of a mere 0.01 µg ml-1. Ivermectin B1a, the major (80%) component of commercially available ivermectin, proved to be inactive, and it was the minor (20%) component, ivermectin B1b, which caused snail death. Snail egg-masses were not affected, even at the highest concentration of 100 µg ml-1. With respect to S. mansoni parasite stages, 0.2 µg ml-1 ivermectin killed 50% of cercariae and miracidia within five minutes, rising to 90% after 30 min. Mortality of guppy fish within 24 h of exposure to ivermectin at concentrations of 0.5 µg ml-1 and 0.01 µg ml-1, were 100% and 30%, respectively. The concentration of 0.01 µg ml-1 that killed Schistosoma mansoni-infected snails only caused 30% mortality in guppy fish. Ivermectin can be considered a promising molluscicide, especially as it is more potent against infected snails than uninfected ones, although it has no impact on egg-masses. Ivermectin and its derivatives could be explored in the search for a new agent to help control schistosomiasis transmission.
Subject(s)
Antiparasitic Agents/pharmacology , Biomphalaria/parasitology , Ivermectin/pharmacology , Schistosoma mansoni/drug effects , Schistosomiasis mansoni/drug therapy , Animals , Antiparasitic Agents/administration & dosage , Dose-Response Relationship, Drug , Ivermectin/administration & dosage , Lethal Dose 50 , Schistosoma mansoni/isolation & purification , Schistosomiasis mansoni/parasitology , Time FactorsABSTRACT
A atividade esquistossomicida do carvacrol e do acetato de carvacrol foi avaliada utilizando-se camundongos Swiss, com peso aproximado de 20g, infectados com cercarias de Schistosoma mansoni. Os experimentos in vitro e in vivo foram realizados conforme a metodologia descrita no tópico específico do presente artigo. Nos dois experimentos in vitro, as concentrações foram de 4 µg/mL ou 8µg/mL. Nas experiências in vivo, um grupo de dez animais foi tratado, por via oral, com 300mg/kg durante cinco dias consecutivos e, em outros dois grupos também de dez animais, foram administradas, por via oral, as doses únicas de 15 mg/kg ou 30 mg/kg. Os dois compostos mostraram-se ativos na concentração de 4µg/mL, causando a morte dos vermes adultos de S. mansoni em menos de 24 horas de contato, quando os testes foram realizados in vitro. Nos experimentos in vivo, considerados os três esquemas terapêuticos utilizados, não se observou diferença significativa na eficácia dos compostos. Diante dos resultados obtidos, conclui-se que os compostos estudados são viáveis para estudos in vitro, mas não apresentam atividade in vivo, indicando que testes in vitro não são suficientes para caracterizar um agente esquistossomicida. A falta de atividade in vivo sugere que estes compostos, na forma utilizada, não podem ser considerados como esquistossomicidas para uso clínico. É importante ter em mente que, apesar de útil, a abordagem in vitro é uma simulação da realidade, mas, definitivamente, uma abordagem não substituirá a outra
Subject(s)
Schistosoma mansoni , Schistosomiasis , Drug TherapyABSTRACT
Schistosome-host interaction is influenced by multiple factors, such as the type of immune response developed by the host, host genetic background, intensity, and number of infections. Those factors not only affect the development and elimination of Schistosoma mansoni , but also the pathology triggered by infection with this parasite. In the present study, we assessed the parasitological, pathological, and immunological aspects elicited by infection and reinfection in 2 different mouse strains commonly used as models in studies on schistosomiasis: BALB/c and C57BL/6. No differences in worm burden recovery or in the number of eggs per gram of intestine or feces were observed between the strains or between infected and reinfected mice from the same strain. However, the number of eggs trapped in the liver of the reinfected mice was significantly higher than the number of eggs in the liver of the infected animals. But, the granulomatous area was significantly lower in reinfected animals than in infected ones. Additionally, granuloma in the infected BALB/c mice was greater than in infected C57BL/6 animals. Regarding the cytokine profile, spleen cells from the infected/reinfected C57BL/6 mice produced higher interleukin 10 (IL-10) levels against egg antigens than BALB/c-infected/reinfected mice. BALB/c mice, in contrast, produced significantly higher IL-4 and IL-13 cytokines after infection/reinfection than the C57BL/6 mice, with the highest levels of IL-13 being observed after reinfection. Our results demonstrate that, although different host backgrounds did not impact resistance to S. mansoni , they result in different immunological profiles that suggest different pathological impacts on the liver.
Subject(s)
Schistosoma mansoni/immunology , Schistosomiasis mansoni/parasitology , Animals , Cytokines/metabolism , Feces/parasitology , Female , Granuloma/parasitology , Granuloma/pathology , Intestines/parasitology , Liver/parasitology , Liver/pathology , Liver Diseases/parasitology , Liver Diseases/pathology , Mice , Mice, Inbred BALB C , Mice, Inbred C57BL , Parasite Egg Count , Recurrence , Schistosoma mansoni/isolation & purification , Schistosoma mansoni/physiology , Schistosomiasis mansoni/immunology , Schistosomiasis mansoni/pathology , Spleen/cytology , Spleen/immunologyABSTRACT
BACKGROUND: A vaccine against schistosomiasis would have a great impact in disease elimination. Sm29 and Sm22.6 are two parasite tegument proteins which represent promising antigens to compose a vaccine. These antigens have been associated with resistance to infection and reinfection in individuals living in endemic area for the disease and induced partial protection when evaluated in immunization trials using naïve mice. METHODOLOGY/PRINCIPALS FINDINGS: In this study we evaluated rSm29 and rSm22.6 ability to induce protection in Balb/c mice that had been previously infected with S. mansoni and further treated with Praziquantel. Our results demonstrate that three doses of the vaccine containing rSm29 were necessary to elicit significant protection (26%-48%). Immunization of mice with rSm29 induced a significant production of IL-2, IFN-γ, IL-17, IL-4; significant production of specific antibodies; increased percentage of CD4+ central memory cells in comparison with infected and treated saline group and increased percentage of CD4+ effector memory cells in comparison with naïve Balb/c mice immunized with rSm29. On the other hand, although immunization with Sm22.6 induced a robust immune response, it failed to induce protection. CONCLUSION/SIGNIFICANCE: Our results demonstrate that rSm29 retains its ability to induce protection in previously infected animals, reinforcing its potential as a vaccine candidate.
Subject(s)
Antigens, Helminth/immunology , Helminth Proteins/immunology , Membrane Glycoproteins/immunology , Schistosomiasis mansoni/immunology , Animals , Antibodies, Helminth/blood , CD4-Positive T-Lymphocytes/immunology , Cytokines/blood , Female , Humans , Immunization , Immunoglobulin G/blood , Immunologic Memory , Mice , Mice, Inbred BALB C , Mice, Inbred C57BL , Schistosoma mansoni/immunology , Vaccines/immunologyABSTRACT
BACKGROUND: Protein kinases are proven targets for drug development with an increasing number of eukaryotic Protein Kinase (ePK) inhibitors now approved as drugs. Mitogen-activated protein kinase (MAPK) family members connect cell-surface receptors to regulatory targets within cells and influence a number of tissue-specific biological activities such as cell proliferation, differentiation and survival. However, the contributions of members of the MAPK pathway to schistosome development and survival are unclear. METHODOLOGY/PRINCIPAL FINDINGS: We employed RNA interference (RNAi) to elucidate the functional roles of five S. mansoni genes (SmCaMK2, SmJNK, SmERK1, SmERK2 and SmRas) involved in MAPK signaling pathway. Mice were injected with post-infective larvae (schistosomula) subsequent to RNAi and the development of adult worms observed. The data demonstrate that SmJNK participates in parasite maturation and survival of the parasites, whereas SmERK are involved in egg production as infected mice had significantly lower egg burdens with female worms presenting underdeveloped ovaries. Furthermore, it was shown that the c-fos transcription factor was overexpressed in parasites submitted to RNAi of SmERK1, SmJNK and SmCaMK2 indicating its putative involvement in gene regulation in this parasite's MAPK signaling cascade. CONCLUSIONS: We conclude that MAPKs proteins play important roles in the parasite in vivo survival, being essential for normal development and successful survival and reproduction of the schistosome parasite. Moreover SmERK and SmJNK are potential targets for drug development.
Subject(s)
Helminth Proteins/metabolism , MAP Kinase Signaling System , Mitogen-Activated Protein Kinases/metabolism , Schistosoma mansoni/growth & development , Animals , Female , Fertility , Gene Expression Regulation , Genes, Helminth , Helminth Proteins/genetics , Male , Mice , Mitogen-Activated Protein Kinases/genetics , Ovary/growth & development , Parasite Egg Count , Protein Kinase Inhibitors/pharmacology , RNA Interference , Reproduction , Schistosoma mansoni/geneticsABSTRACT
BACKGROUND: Schistosomiasis has a considerable impact on public health in many tropical and subtropical areas. In the new world, schistosomiasis is caused by the digenetic trematode Schistosoma mansoni. Chemotherapy is the main measure for controlling schistosomiasis, and the current drug of choice for treatment is praziquantel (PZQ). Although PZQ is efficient and safe, its repetitive large-scale use in endemic areas may lead to the selection of resistant strains. Isolates less susceptible to PZQ have been found in the field and selected for in the laboratory. The impact of selecting strains with a decreased susceptibility phenotype on disease dynamics and parasite population genetics is not fully understood. This study addresses the impact of PZQ pressure on the genetics of a laboratory population by analyzing frequency variations of polymorphic genetic markers. METHODOLOGY: Infected mice were treated with increasing PZQ doses until the highest dose of 3 × 300 mg/Kg was reached. The effect of PZQ treatment on the parasite population was assessed using five polymorphic microsatellite markers. Parasitological and genetic data were compared with those of the untreated control. After six parasite generations submitted to treatment, it was possible to obtain a S. mansoni population with decreased susceptibility to PZQ. In our experiments we also observed that female worms were more susceptible to PZQ than male worms. CONCLUSIONS: The selective pressure exerted by PZQ led to decreased genetic variability in S. mansoni and increased endogamy. The understanding of how S. mansoni populations respond to successive drug pressure has important implications on the appearance and maintenance of a PZQ resistance phenotype in endemic regions.
Subject(s)
Anthelmintics/therapeutic use , Genetic Variation , Praziquantel/therapeutic use , Schistosoma mansoni/classification , Schistosoma mansoni/genetics , Schistosomiasis mansoni/drug therapy , Schistosomiasis mansoni/parasitology , Animals , Drug Resistance , Female , Male , Mice , Microsatellite Repeats , Schistosoma mansoni/isolation & purification , Selection, GeneticABSTRACT
Mice infected with Schistosoma mansoni were treated with oxamniquine, praziquantel, artesunate at the pre-patent phase, aiming at observing schistogram alterations. Half of the animals were perfused five days post-treatment for counting and classification of immature worms, based on pre-established morphological criteria (schistogram); the remaining animals were evaluated 42 or 100 days after infection and perfusion of the portal-system was performed for collection and counting of adult worms and oogram. It was observed that oxamniquine and artesunate treatment administered at the pre-postural phase causes significant reduction in the number of immature and adult worms. However, there was little reduction with praziquantel when used at the dose of 400 mg/kg for treatments administered 14, 15, 21 or 23 days post-infection. Artesunate was responsible for significant alterations in development of young worms, as well as for a higher number of worms presenting intestinal damages. Immature adult worms were detected in mice treated with artesunate or oxamniquine at the pre-patent phase of infection and recovered by perfusion 100 days after infection. Schistogram proved to be a very useful tool for experimental evaluation of the activity of antischistosomal drugs and a good model to identify the most sensitive stages to drugs.
Subject(s)
Artemisinins/therapeutic use , Schistosoma mansoni/drug effects , Schistosomiasis mansoni/drug therapy , Schistosomicides/therapeutic use , Animals , Artesunate , Drug Therapy, Combination/methods , Female , Mice , Oxamniquine/therapeutic use , Parasite Egg Count , Parasitemia/drug therapy , Praziquantel/therapeutic use , Schistosoma mansoni/growth & developmentABSTRACT
Mice infected with Schistosoma mansoni were treated with oxamniquine, praziquantel, artesunate at the pre-patent phase, aiming at observing schistogram alterations. Half of the animals were perfused five days post-treatment for counting and classification of immature worms, based on pre-established morphological criteria (schistogram); the remaining animals were evaluated 42 or 100 days after infection and perfusion of the portal-system was performed for collection and counting of adult worms and oogram. It was observed that oxamniquine and artesunate treatment administered at the pre-postural phase causes significant reduction in the number of immature and adult worms. However, there was little reduction with praziquantel when used at the dose of 400 mg/kg for treatments administered 14, 15, 21 or 23 days post-infection. Artesunate was responsible for significant alterations in development of young worms, as well as for a higher number of worms presenting intestinal damages. Immature adult worms were detected in mice treated with artesunate or oxamniquine at the pre-patent phase of infection and recovered by perfusion 100 days after infection. Schistogram proved to be a very useful tool for experimental evaluation of the activity of antischistosomal drugs and a good model to identify the most sensitive stages to drugs.
Subject(s)
Animals , Female , Mice , Artemisinins/therapeutic use , Schistosoma mansoni/drug effects , Schistosomiasis mansoni/drug therapy , Schistosomicides/therapeutic use , Drug Therapy, Combination/methods , Oxamniquine/therapeutic use , Parasite Egg Count , Parasitemia/drug therapy , Praziquantel/therapeutic use , Schistosoma mansoni/growth & developmentABSTRACT
Imatinib, a drug used for treatment of human chronic myeloid leukaemia, due to its activity against protein kinases, has been also evaluated in vitro against Schistosoma mansoni showing high schistosomicidal activity. In the present experiments imatinib activity in vitro was confirmed at the doses of 25 µM, 50 µM and 100 µM. The first drug activity observed with the lower dose was interruption of egg-laying and with the higher dosages was the death of the worms. In mice infected with S. mansoni no activity was found even with 1,000 mg/kg/day, 500 mg/kg/day, single oral dose or when administered for three consecutive days. This is another example of the difference of results related to in vitro and in vivo trials using S. mansoni worms.
Subject(s)
Animals , Mice , Benzamides/pharmacology , Piperazines/pharmacology , Pyrimidines/pharmacology , Schistosoma mansoni/drug effects , Schistosomiasis mansoni/drug therapy , Schistosomicides/pharmacology , Dose-Response Relationship, Drug , Parasite Load , Schistosomiasis mansoni/parasitology , Time FactorsABSTRACT
Imatinib, a drug used for treatment of human chronic myeloid leukaemia, due to its activity against protein kinases, has been also evaluated in vitro against Schistosoma mansoni showing high schistosomicidal activity. In the present experiments imatinib activity in vitro was confirmed at the doses of 25 µM, 50 µM and 100 µM. The first drug activity observed with the lower dose was interruption of egg-laying and with the higher dosages was the death of the worms. In mice infected with S. mansoni no activity was found even with 1,000 mg/kg/day, 500 mg/kg/day, single oral dose or when administered for three consecutive days. This is another example of the difference of results related to in vitro and in vivo trials using S. mansoni worms.
Subject(s)
Benzamides/pharmacology , Piperazines/pharmacology , Pyrimidines/pharmacology , Schistosoma mansoni/drug effects , Schistosomiasis mansoni/drug therapy , Schistosomicides/pharmacology , Animals , Dose-Response Relationship, Drug , Imatinib Mesylate , Mice , Parasite Load , Schistosomiasis mansoni/parasitology , Time FactorsABSTRACT
Current schistosomiasis control strategies are largely based on chemotherapeutic agents and a limited number of drugs are available today. Praziquantel (PZQ) is the only drug currently used in schistosomiasis control programs. Unfortunately, this drug shows poor efficacy in patients during the earliest infection phases. The effects of PZQ appear to operate on the voltage-operated Ca2+ channels, which are located on the external Schistosoma mansoni membrane. Because some Ca2+ channels have dihydropyridine drug class (a class that includes nifedipine) sensitivity, an in vitro analysis using a calcium channel antagonist (clinically used for cardiovascular hypertension) was performed to determine the antischistosomal effects of nifedipine on schistosomula and adult worm cultures. Nifedipine demonstrated antischistosomal activity against schistosomula and significantly reduced viability at all of the concentrations used alone or in combination with PZQ. In contrast, PZQ did not show significant efficacy when used alone. Adult worms were also affected by nifedipine after a 24 h incubation and exhibited impaired motility, several lesions on the tegument and intense contractility. These data support the idea of Ca2+ channels subunits as drug targets and favour alternative therapeutic schemes when drug resistance has been reported. In this paper, strong arguments encouraging drug research are presented, with a focus on exploring schistosomal Ca2+ channels.
Subject(s)
Calcium Channel Blockers/pharmacology , Nifedipine/pharmacology , Praziquantel/pharmacology , Schistosoma mansoni/drug effects , Schistosomicides/pharmacology , Animals , Mice , Parasitic Sensitivity TestsABSTRACT
Current schistosomiasis control strategies are largely based on chemotherapeutic agents and a limited number of drugs are available today. Praziquantel (PZQ) is the only drug currently used in schistosomiasis control programs. Unfortunately, this drug shows poor efficacy in patients during the earliest infection phases. The effects of PZQ appear to operate on the voltage-operated Ca2+channels, which are located on the external Schistosoma mansoni membrane. Because some Ca2+channels have dihydropyridine drug class (a class that includes nifedipine) sensitivity, an in vitro analysis using a calcium channel antagonist (clinically used for cardiovascular hypertension) was performed to determine the antischistosomal effects of nifedipine on schistosomula and adult worm cultures. Nifedipine demonstrated antischistosomal activity against schistosomula and significantly reduced viability at all of the concentrations used alone or in combination with PZQ. In contrast, PZQ did not show significant efficacy when used alone. Adult worms were also affected by nifedipine after a 24 h incubation and exhibited impaired motility, several lesions on the tegument and intense contractility. These data support the idea of Ca2+channels subunits as drug targets and favour alternative therapeutic schemes when drug resistance has been reported. In this paper, strong arguments encouraging drug research are presented, with a focus on exploring schistosomal Ca2+channels.
Subject(s)
Animals , Mice , Calcium Channel Blockers/pharmacology , Nifedipine/pharmacology , Praziquantel/pharmacology , Schistosoma mansoni/drug effects , Schistosomicides/pharmacology , Parasitic Sensitivity TestsABSTRACT
If Schistosoma mansoni infection could be detected in its early stages, especially before the egg deposition in the host tissues, the development of severe pathologic lesions could be efficiently prevented. We therefore developed an indirect enzyme-linked immunosorbent assay based on the detection of specific IgG against schistosomula antigens (ELISA-SmTeg). The assay was applied in sera samples from non-infected and infected mice collected seven and 15 days post-infection. The results were compared to the number of adult worms obtained by perfusion of the murine hepatic system 50 days post-infection. The sensitivity and specificity of the ELISA-SmTeg were 100% (p = 0.0032 and 0.0048 respectively for seven and 15 days of infection) with a cutoff value of 0.15 (p = 0.0002). Our findings show a novel low-cost serological assay using antigens which are easy to obtain, which was able to detect all the infected mice as early as seven days post-infection.
Subject(s)
Antibodies, Helminth/blood , Antigens, Helminth/immunology , Immunoglobulin G/blood , Schistosoma mansoni/immunology , Schistosomiasis mansoni/diagnosis , Animals , Antibodies, Helminth/immunology , Early Diagnosis , Enzyme-Linked Immunosorbent Assay/methods , Female , Immunoglobulin G/immunology , Mice , Parasite Egg Count , Sensitivity and SpecificityABSTRACT
If Schistosoma mansoni infection could be detected in its early stages, especially before the egg deposition in the host tissues, the development of severe pathologic lesions could be efficiently prevented. We therefore developed an indirect enzyme-linked immunosorbent assay based on the detection of specific IgG against schistosomula antigens (ELISA-SmTeg). The assay was applied in sera samples from non-infected and infected mice collected seven and 15 days post-infection. The results were compared to the number of adult worms obtained by perfusion of the murine hepatic system 50 days post-infection. The sensitivity and specificity of the ELISA-SmTeg were 100% (p = 0.0032 and 0.0048 respectively for seven and 15 days of infection) with a cutoff value of 0.15 (p = 0.0002). Our findings show a novel low-cost serological assay using antigens which are easy to obtain, which was able to detect all the infected mice as early as seven days post-infection.
A detecção da infecção pelo helminto Schistosoma mansoni quando realizada nas fases iniciais, especialmente antes da oviposição nos tecidos do hospedeiro, pode impedir de forma eficiente o desenvolvimento de graves lesões patológicas. Baseado nisto, foi desenvolvido um ensaio imunoenzimático indireto para detecção de anticorpos IgG específicos contra antígenos de esquistossômulos (ELISA-SmTeg). Este ensaio foi aplicado em amostras sorológicas de camundongos não infectados, da mesma forma que de camundongos recentemente infectados, após sete e 15 dias de infecção. Os resultados foram comparados com o número de vermes adultos obtidos por perfusão do sistema hepático murino 50 dias pós-infecção. A sensibilidade e a especificidade do novo método, denominado ELISA-SmTeg, foram de 100% (p = 0,0032, 0,0048, respectivamente, durante sete e 15 dias de infecção) com um valor de corte de 0,15 (p = 0,0002). Nossos resultados mostraram que um ensaio de baixo custo, que utiliza antígenos de fácil obtenção, é capaz de discriminar a esquistossomose mansoni em modelo experimental de forma precoce, incluindo sete dias pós-infecção.
Subject(s)
Animals , Female , Mice , Antibodies, Helminth/blood , Antigens, Helminth/immunology , Immunoglobulin G/blood , Schistosoma mansoni/immunology , Schistosomiasis mansoni/diagnosis , Antibodies, Helminth/immunology , Early Diagnosis , Enzyme-Linked Immunosorbent Assay/methods , Immunoglobulin G/immunology , Parasite Egg Count , Sensitivity and SpecificityABSTRACT
In schistosomiasis, the current control strategy does not prevent reinfection, therefore, vaccine strategies are essential to combat the Schistosoma mansoni. The efficacy vaccine depends on parasite stage and effective adjuvant. We have recently demonstrated that S. mansoni schistosomula tegument (Smteg) is able to activate dendritic cells up regulate CD40 and CD86 molecules and induce a partial protection in mice (43-48%) when formulated with Freund's adjuvant. In this study we evaluated the ability of Smteg + alum or Smteg + alum + CpG-ODN to induce protection in mice. Our results demonstrate that Smteg + alum + CpG-ODN induced a partial reduction in worm burden (43.1%), reduction in the number of eggs eliminated in the feces. The protective response was associated with a predominant Th1 type of immune response, with increased production of specific IgG2c, IFN-γ and TNF-α, B cells proliferation and CD4 cells and macrophages activation.